OR-USB-IF
27.8.2024 17:01:25 CEST | Business Wire | Press release
USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced the launch of the USB-IF Conformity to IEC 62680 (USB) Specifications Program. This new initiative is designed to assist Original Equipment Manufacturers (OEMs)/Original Device Manufacturers (ODMs) in conforming to the basic requirements of the European Union (EU) Common Charger Directive, which mandates the use of standardized charging technology across a wide range of portable battery-powered devices in the EU.
In response to the EU's 2022 approval of the common charger directive—which will take effect on January 1, 2025, for portable battery-powered devices and in 2026 for laptops—the USB-IF Conformity to IEC 62680 (USB) Specifications Program specifically addresses key aspects of the directive. These include portable battery-powered devices, USB Type-C® receptacles, USB Type-C cables and connectors, external power supplies (EPS), and the USB Power Delivery (USB PD) protocol for devices advertising more than 15 Watts.
“The USB-IF has enjoyed a longstanding relationship with IEC. We contributed the core USB specifications to IEC which, once adopted, became the IEC 62680 series of USB specifications,” said USB-IF President and Chief Operating Officer Jeff Ravencraft. “The EU mandate covers only a portion of the entire USB specifications. As the industry group responsible for developing and overseeing all aspects of the USB specifications and testing, the USB-IF's new program is designed to assist OEMs/ODMs in demonstrating conformity with the EU’s requirements of the common charger directive.”
The USB-IF Conformity to IEC 62680 (USB) Specifications Program creates a simple, cost-effective process for OEMs/ODMs to demonstrate conformity to the EU Common Charger Directive. Using the USB-IF program, OEMs/ODMs can have their USB Type-C products formally tested by USB-IF authorized independent test labs (ITLs). Upon successful completion of testing, OEMs/ODMs will receive documentation to demonstrate to the EU that their products conform to the IEC 62680 (USB) specifications. This streamlined process allows for a quick testing turnaround, ensuring that manufacturers can meet regulatory deadlines:
- OEMs will continue to register their products and submit test results through ITLs, following USB-IF’s already established process.
- A minimum set of required tests has been defined by the USB-IF to demonstrate baseline conformity.
- The USB-IF will review all test result submissions and provide official approval.
- A Vendor ID (VID) is required, and USB-IF will be utilizing a Test ID (TID) as a tracker reference.
"The USB-IF Conformity to IEC 62680 (USB) Specifications Program has been crafted to ensure that all submitted products undergo evaluation, focusing on the critical elements we believe are necessary for conforming with the EU mandate,” said USB-IF Chief Technology Officer and Chairman of the Board Abdul Ismail. “Our testing levels are designed to offer a precise and reliable assessment, enabling OEMs/ODMs to confidently show to the EU that their products conform to the regulatory obligations."
While the USB-IF Conformity to IEC 62680 (USB) Specifications Program provides a vital service to OEMs/ODMs by offering a formal method to demonstrate conformity to EU mandates, it is important to distinguish this from the more extensive USB-IF Compliance Program. The USB-IF Compliance Program offers in-depth testing that not only establishes conformity with the IEC 62680 specifications but also fully verifies a product's adherence to the comprehensive USB-IF specifications for data performance, reliability and interoperability. Additionally, fully certified products qualify to be able to use the Certified USB Logo, which consumers recognize and trust to provide what they have come to expect from USB products.
“While this program is not a full certification of USB technologies, it provides a formalized pathway for OEMs/ODMs to test their products quickly,” said Ravencraft. “We are confident this new program will help the industry achieve conformity so they can continue to sell their products in the EU marketplace."
An online public listing of OEMs/ODMs products that have passed the "USB-IF Conformity to IEC 62680 (USB) Specifications Program" is located on the USB-IF product search page at www.usb.org. This platform also differentiates between products that are fully USB-IF certified and those that have met only the conformity requirements.
About USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827576634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom